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The morphology of cervical cancer referred for definitive 
radio-chemotherapy varies considerably ranging from 
expansive tumours confined to the cervix (stage IB) to 
irregular and infiltrating tumours involving the parametria 
(stage IIB), further to  the pelvic wall (stage IIIB), or to the 
distal part of the vagina (stage IIIA). Bladder and rectum may 
also be involved (stage IVA) as well as the corpus uteri. In 
addition to this morphological heterogeneity at diagnosis, 
additional variability arises as significant tumour regression 
often occur already during the first 2-3 weeks of external 
beam radiotherapy (EBRT).  
Local tumour control in cervical cancer require significant 
dose which is achieved with the application of brachytherapy 
(BT), typically going from a dose level of about 45 Gy 
obtained with EBRT to a dose level of more than 90 Gy 
covering at least 90% of the target volume. Due to the steep 
dose gradients involved in BT even higher dose levels well 
above 100 Gy is then reached in the central part of the 
tumour.  
BT has traditionally been administered by use of fixed 
standard plans delivering certain doses to specific points 
defined in 2D in relation to the BT applicator (point-A) rather 
than adapted to the changing morphology of the cervix 
tumour. However, during the last decade a significant change 
in clinical practice has taken place towards using a dynamic 
target concept developed by the GEC ESTRO gynaecological 
working group. This 4D target concept enables the delivery of 
adaptive levels of BT dose to the tumour extension at both 
diagnosis (intermediate-risk CTV) and remaining tumour and 
cervix at time of BT (high-risk CTV). To obtain maximal 
advantage of the initial tumour regression during EBRT, but 
also to avoid deleterious repopulation, the application of BT 
is normally performed  during the final weeks of a 6-8 week 
overall treatment time. To fulfil the ambitious planning aims 
of reaching >90 Gy in the high-risk CTV and >60 Gy in the 
intermediate-risk CTV with out overdosing the near by organs 
at risk new application techniques for BT has been developed 
employing combined intracavitary-interstial applicators. In 
centres experienced in image guided BT the new 
intracavitary/interstitial technique is now employed in 
almost 50% of the patients. 
Single centre series with significant patient numbers have 
already demonstrated improved local control and survival 
with morphology adapted BT especially in large tumours even 
surpassing the effect found for concomitant cisplatin 15 years 
ago. In addition, the risk of severe urologic and gastro-
intestinal morbidity has been significantly reduced. 
Multicentre studies including quality of life endpoints are 
now maturing pointing to specific dose response curves for 
tumour control and dose effect curves for morbidity. These 
impending findings will further expand the therapeutic 
window in cervix cancer radiotherapy as these new principles 
for image guided BT with evidence based planning aims and 
constraints find their way into the clinics around the world. 
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Biologically individualized treatment by integration of 
biological data and respective adaptation of treatment is 
major field of research and has a great potential to prove the 
concept of personalized oncology to provide a benefit to 
patients. The potential benefit may result from descalation 
in patients with good-risk tumours, targeted escalation in 
intermediate-risk patients and assigning patients with high-
risk tumours to novel approaches to overcome radiation 
resistance. Innovations in functional imaging, biomarker 
research, data modelling, high-precision treatment planning 
and delivery within the context of better radiobiological 
understanding and careful consideration of established 
clinical factors enables translational and clincial research 
into dose painting, adaptation according to temporal changes 
and model-based treatment prescriptions.  
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Purpose/Objective: Image guided adaptive brachytherapy 
(IGABT), has transformed treatment for locally advanced 
cervical cancer considerably. Dose adaptation and combined 
intracavitary/interstitial (IC/IS) applicators have significantly 
changed dose and volume parameters for targets and organs 
at risk, resulting in improved outcomes. This study aimed to 
evaluate the impact of IC/IS brachytherapy on late morbidity 
on which, to date, there is little data. 
Materials and Methods: Seven hundred and thirty one 
patients with locally advanced cervical cancer were enrolled 
in the retroEMBRACE study from 12 institutions. Detailed 
information on grade 1-5 toxicity (CTCAE,V3.0) following 
IGABT was captured in 610 patients enrolled from 8 
institutions. These patients were analysed in the present 
study. Based on technique, patients were divided into two 
groups. One group (N=300) referred to as advanced adaptive 
(AD) included all patients from the empirical time point, 
when an institution used IC/IS technique systematically in 
more than 20% of the cases. The other group (N=310), 
referred to as limited adaptive (LA), included all other 
patients where the most frequent technique used was 
intracavitary. 
Results: Patient related factors such as age, FIGO stage, 
tumour width, lymph node status and follow up time were 
equally distributed between the groups. No difference in 
EBRT target volumes, doses and fractionation schedule was 
